BAFFR Allo CAR-NK

N/A

Report date: 2025/03/18 18:02:53

Base Information

Drug NameBAFFR Allo CAR-NK
Drug Alias Nameanti-BAFF-R CAR NK-cell therapy (PeproMene)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionB-cell activating factor receptor inhibitors
TargetsB-cell activating factor receptor
Therapy Area/IndicationsImmune System DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPeproMene Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesPeproMene Bio Inc
Inactive CompaniesN/A
Active IndicationsImmune System DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A